Sołowow invests in cancer fighting enterprise

Michał Sołowow has become a key shareholder, via IPOPEMA 112 FIZ AN, of NanoVelos biotechnology firm which specializes in cancer treatment. "The current investment round is meant to launch the clinical study of the NanoVelos' nanoparticles carying doxorubicin," a press release read. "NanoVelos' funding needs have been satisfied for the next 12 months. I am ready for further investments," Puls Biznesu reported citing Sołowow. NanoVelos nanotechnology transports toxic substances which kill cancer cells directly to the infected cells. The value of the investment has not been revealed. This is Sołowow's second investment in a project related with cancer treatment. Previously, the entrepreneur started cooperation with OncoArendi Therapeutics.